News headlines about Celgene (NASDAQ:CELG) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Celgene earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 46.2097422124398 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news articles that may have effected Accern’s rankings:
- Celgene (CELG) Reports OTEZLA (Apremilast) Phase III Data Showed Significant Improvements in Patients with Active Behçet’s Disease with Oral Ulcers (streetinsider.com)
- Celgene Co. (CELG) Expected to Announce Quarterly Sales of $3.50 Billion (americanbankingnews.com)
- Celgene Co. (CELG) Director Gilla Kaplan Sells 9,250 Shares (americanbankingnews.com)
- Gilla Kaplan Sells 9,250 Shares of Celgene Co. (CELG) Stock (americanbankingnews.com)
- Orphan Diseases Market Outlook 2018 | Size, Potential, Growth and Trend | A Definite Shift towards the Developing World | Forecasts till 2022 (medgadget.com)
Celgene (NASDAQ CELG) traded up $0.04 during trading on Wednesday, reaching $93.89. The company had a trading volume of 4,179,650 shares, compared to its average volume of 8,390,000. The firm has a market capitalization of $70,620.00, a price-to-earnings ratio of 17.88, a P/E/G ratio of 0.67 and a beta of 1.49. Celgene has a 52-week low of $88.32 and a 52-week high of $147.17. The company has a debt-to-equity ratio of 2.29, a current ratio of 4.99 and a quick ratio of 4.80.
Celgene declared that its board has approved a stock buyback plan on Wednesday, February 14th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the biopharmaceutical company to purchase shares of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its stock is undervalued.
CELG has been the topic of a number of research analyst reports. JPMorgan Chase & Co. set a $123.00 target price on Celgene and gave the stock a “buy” rating in a research report on Friday, October 27th. UBS Group decreased their target price on Celgene from $146.00 to $120.00 and set a “buy” rating on the stock in a research report on Friday, October 27th. Canaccord Genuity reiterated a “buy” rating and set a $140.00 target price (down from $154.00) on shares of Celgene in a research report on Friday, October 27th. SunTrust Banks decreased their target price on Celgene from $156.00 to $127.00 and set a “buy” rating on the stock in a research report on Friday, October 27th. Finally, Cann reiterated a “buy” rating on shares of Celgene in a research report on Thursday, October 26th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating, eighteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $130.25.
In other Celgene news, Director Gilla Kaplan sold 9,250 shares of the company’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $95.99, for a total transaction of $887,907.50. Following the completion of the sale, the director now directly owns 94,801 shares in the company, valued at $9,099,947.99. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Mark J. Alles purchased 3,260 shares of the company’s stock in a transaction on Thursday, February 8th. The shares were purchased at an average price of $91.90 per share, with a total value of $299,594.00. Following the completion of the purchase, the insider now directly owns 178,904 shares of the company’s stock, valued at $16,441,277.60. The disclosure for this purchase can be found here. Corporate insiders own 0.95% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was posted by BBNS and is the sole property of of BBNS. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://baseballnewssource.com/markets/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-celgene-celg-stock-price/1899425.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.